A Scientific Rationale for Using Cystic Fibrosis Transmembrane Conductance Regulator Therapeutics in COVID-19 Patients

Several pathological manifestations in coronavirus disease 2019 (COVID-19), including thick mucus, poor mucociliary clearance, and bronchial wall thickening, overlap with cystic fibrosis disease patterns and may be indicative of “acquired” cystic fibrosis transmembrane conductance regulator (CFTR) d...

Descripción completa

Detalles Bibliográficos
Autores principales: Lidington, Darcy, Bolz, Steffen-Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Physiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672116/
https://www.ncbi.nlm.nih.gov/pubmed/33250777
http://dx.doi.org/10.3389/fphys.2020.583862

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672116/
https://www.ncbi.nlm.nih.gov/pubmed/33250777
http://dx.doi.org/10.3389/fphys.2020.583862

Ejemplares similares